Cullinan Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Cambridge, Massachusetts that develops experimental therapies for cancer and autoimmune diseases, advancing drug candidates it discovers or licenses through early clinical trials. Founded in 2016 as Cullinan Pharmaceuticals, it rebranded to Cullinan Therapeutics in 2024 to signal its shift beyond oncology into autoimmune conditions. Its name nods to the Cullinan Diamond, the largest gem-quality rough diamond ever found, evoking rarity and brilliance.
Bought 1.87M
Granted 350.9K · Sold 163.7K
Sold 143.9K
Granted 140.4K
Sold 468.6K
Sold 101.9K
Bought 2.14M
Granted 87.0K · Sold 11.0K
Granted 450.6K · Bought 8.1K · Sold 67.9K
Granted 227.9K · Sold 180.0K
Granted 119.1K
Granted 337.5K · Sold 195.6K
Granted 187.5K · Sold 27.5K
Granted 161.5K · Sold 29.8K
Granted 147.0K · Sold 20.9K
Granted 128.8K · Sold 4.4K
Granted 32.5K · Sold 56.2K
Granted 22.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP +1 co-filer10% owner · 8 transactions | — | 8.96M | — | 1.87M | — |
| Gadicke Ansbert10% owner, Former Director · 29 transactions | — | 7.65Mas of Feb 2023 | 350.9K | — | 163.7K |
| BioImpact Capital LLC +2 co-filers10% owner · 14 transactions | -1.8% | 7.65Mas of Sep 2021 | — | — | 143.9K |
| Jovan-Embiricos Morana10% owner · 3 transactions | — | 4.57Mas of Jun 2022 | 140.4K | — | — |
| F2 Vision SCS +1 co-filer10% owner · 8 transactions | — | 4.48Mas of Aug 2022 | — | — | 468.6K |
| F2 Bioscience I 2017 Ltd +1 co-filer10% owner · 3 transactions | — | 4.43Mas of Jun 2022 | — | — | 101.9K |
| Biotechnology Value Fund II LP +9 co-filersSee Explanation of Responses, 10% owner · 13 transactions | — | 558.9Kas of Jan 2023 | — | 2.14M | — |
| Baeuerle PatrickChief Scientific Officer · 4 transactions | +18.4% | 417.4Kas of Feb 2023 | 87.0K | — | 11.0K |
| Ahmed NadimPresident and CEO, Director · 15 transactions | — | 390.8K | 450.6K | 8.1K | 67.9K |
| Savill CorrineChief Business Officer · 17 transactions | +24.8% | 241.0Kas of Feb 2025 | 227.9K | — | 180.0K |
| Ebeling ThomasDirector · 3 transactions | +176.5% | 186.7Kas of Jun 2024 | 119.1K | — | — |
| Michaelson JenniferChief Scientific Officer · 66 transactions | +627.1% | 174.8K | 337.5K | — | 195.6K |
| Jones Jeffrey AlanChief Medical Officer · 14 transactions | — | 160.0K | 187.5K | — | 27.5K |
| Trigilio JeffreyChief Financial Officer · 21 transactions | +5852% | 133.9Kas of Feb 2024 | 161.5K | — | 29.8K |
| Sumer Jacquelyn LChief Legal Officer · 14 transactions | — | 128.1K | 147.0K | — | 20.9K |
| Fenton Mary KayChief Financial Officer · 4 transactions | — | 126.4K | 128.8K | — | 4.4K |
| Zawel LeighSee Remarks · 5 transactions | -25.4% | 69.8Kas of Feb 2022 | 32.5K | — | 56.2K |
| Keane Raymond TChief Legal Officer · 1 transaction | +1385.5% | 24.1Kas of Feb 2022 | 22.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +2.55M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.